BIOAGE LABS INC

BIOANASDAQ

🏆 #3495 by market capEarnings Nov 4US Equity

$871.43▼ $42.18 (−4.84%)

Simulated price

🔔

Track BIOA

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$265M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

99.4%

High

💵FCF Margin

-850.7%

Thin

⚖️P/S Ratio

25.6x

Expensive

Otter Score

Good

No chart data available for BIOA.

Trading Snapshot

Day Range: $866.33 – $888.14
52-Week Range: $5.04 – $25.96
Volume: $3.26B
Avg Volume: $3.31B
Shares Outstanding: 37.6M
Next Earnings: Dec 2, 2026

Fundamentals Snapshot

Annual Revenue: $10M
Last Q Revenue: $3M
P/E Ratio: -3.0
P/S Ratio: 25.6x
EPS (TTM): $-2.11
Dividend Yield: 0.00%

Why Investors Own BIOA

✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
✓Healthy economics — 49% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BIOAGE LABS INC

BIOA

Financial Trends

Revenue (TTM)

$10M▲ +11.9% YoY

Gross Margin (TTM)

48.5%▲ +1.6% YoY

Operating Income (TTM)

$3M▲ +11.9% YoY

Free Cash Flow (TTM)

$776,625▲ +11.9% YoY

StockOtter · stockotter.space

About BIOAGE LABS INC

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

🦦